BGB-A317-305 JapicCTI-194799
Active, not recruiting
Tislelizumab in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Gastric, or Gastroesophageal Junction Carcinoma
Beigene Study ID 
BGB-A317-305 JapicCTI-194799
ClinicalTrials.gov ID
EudraCT Number
2018-000312-24
Clinical Drug Trials ID
CTR20181841
Sex:
All
Age: 18 Years and older (Adult, Older Adult)
Accepts Healthy Volunteers? yes
No Study Documents
Sex:
All
Age: 18 Years and older (Adult, Older Adult)
Accepts Healthy Volunteers? yes
No Study Documents
BeiGene provides links to web sites of other organizations in order to provide visitors with certain information. A link does not constitute an endorsement of content, viewpoint, policies, products or services of that web site. Once you link to another web site not maintained byBeiGene Australia, you are subject to the terms and conditions of that web site, including but not limited to its privacy policy.
Click the link above to continue or CANCEL